Stay updated on IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRecruitment status updated to 'No longer looking for participants'. New help sections were added to guide users on reading the study record and joining the study, and the Intervention/Treatment label was updated.SummaryDifference0.4%

- Check20 days agoChange DetectedRevision label updated from v3.5.4 to v3.5.5, indicating a newer page rendering. This appears to be a minor metadata update rather than a substantive content change.SummaryDifference0.0%

- Check42 days agoChange DetectedA new platform revision label Revision: v3.5.4 was added, replacing the previous Revision: v3.5.3. This indicates a backend deployment update with no change to the page content or study details.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check99 days agoChange DetectedRevision history updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.0%

Stay in the know with updates to IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.